GNU Multiple Precision Arithmetic Library

AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada

Retrieved on: 
Tuesday, June 22, 2021
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210622005425/en/
    Rendering of AbCelleras GMP Facility at 900-Block Evans Avenue.
  • The 380,000-square-foot headquarters on 4th Avenue between Columbia and Manitoba Streets will be within walking distance of the new GMP manufacturing facility.
  • The new GMP facility will be built on what is currently a vacant two-acre site, and the planned building will house laboratory, office, GMP protein biologic manufacturing, and warehouse space.
  • The facility is scheduled to be ready for GMP manufacturing in early 2024, and at full capacity will employ hundreds of highly skilled scientific personnel.

XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies

Retrieved on: 
Tuesday, June 15, 2021

The audio press release covers XPhytos recent announcement regarding the status of its GMP mescaline synthesis program.

Key Points: 
  • The audio press release covers XPhytos recent announcement regarding the status of its GMP mescaline synthesis program.
  • To hear the audio production, visit: https://www.nnw.fm/GFUhh
    To read the original press release, visit: https://www.nnw.fm/dcaCA
    "With both its North American GMP mescaline synthesis program and German-based psilocybin biotechnology production underway, the first stage of XPhyto's psychedelic medicine program is progressing on schedule.
  • As the manufacturing programs advance, we look forward to focusing our expertise on psychedelic drug formulation," said Hugh Rogers, CEO & Director.
  • IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions.

DiNAQOR Establishes New GMP Manufacturing Facility in Zurich

Retrieved on: 
Monday, January 11, 2021

ft)GMP facility will produce adeno-associated virus (AAV)-based gene therapies and is co-located with DiNAQOR's Research & Development (R&D) facility.

Key Points: 
  • ft)GMP facility will produce adeno-associated virus (AAV)-based gene therapies and is co-located with DiNAQOR's Research & Development (R&D) facility.
  • "By building our new GMP facility alongside our R&D facility, DiNAQOR will have R&D, Process and Analytical Development, Quality Control and GMP capabilities in the same location, enabling rapid internal collaboration and innovation to accelerate our pipeline advancement toward and through the clinic."
  • The new 1200 sqm manufacturing facility will be in addition to DiNAQOR's R&D facility at Bio-Technopark, more than doubling the Company's current space there.
  • The new GMP facility will be dedicated to establishing a GMP-compatible process in the Process Development labs and provide on-site tech transfer for GMP manufacturing of viral vectors at 500L scale.

The GMP Certification Resource Center developed by InstantGMP and Partners, a GMP Educational Resource for Dietary Supplement, Kratom and Hemp/CBD Producers, is now live!

Retrieved on: 
Wednesday, October 7, 2020

InstantGMP and its partners have created a GMP Certification Resource Center to provide that help.

Key Points: 
  • InstantGMP and its partners have created a GMP Certification Resource Center to provide that help.
  • This is the one site for a comprehensive educational resource for GMP Certification readiness.
  • The training was developed by a team of GMP experts with decades of experience in these industries.
  • The GMP Compliance Partners section provides descriptions and links to services and firms that provide additional assistance in earning GMP Certification.

Kevin M. Sullivan to Propose New Directors for GMP Capital Inc.

Retrieved on: 
Friday, September 4, 2020

Mr. Sullivan also announced that he opposes the most recent terms agreed to between GMP and Richardson Financial Group Limited ("RFGL"), as disclosed on August 13, 2020, by which it is contemplated that GMP would consolidate ownership of 100% of Richardson GMP Limited ("Richardson GMP").

Key Points: 
  • Mr. Sullivan also announced that he opposes the most recent terms agreed to between GMP and Richardson Financial Group Limited ("RFGL"), as disclosed on August 13, 2020, by which it is contemplated that GMP would consolidate ownership of 100% of Richardson GMP Limited ("Richardson GMP").
  • Mr. Sullivan is a substantial shareholder of GMP and devoted almost 25 years of his professional life to its success.
  • Mr. Sullivan beneficially owns, directly or indirectly, an aggregate of 2,982,949 common shares of GMP, or approximately 4.0% of GMP's outstanding common shares.
  • Mr. Sullivan believes that GMP's consolidation of the ownership of Richardson GMP would be in the best interests of GMP, provided that the transaction is undertaken on terms that are fair to all GMP shareholders.

Nanoform Awarded GMP Certification

Retrieved on: 
Monday, May 4, 2020

HELSINKI, May 4, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has been awarded a Good Manufacturing Practices (GMP) certification by the Finnish Medicines Agency, FIMEA.

Key Points: 
  • HELSINKI, May 4, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has been awarded a Good Manufacturing Practices (GMP) certification by the Finnish Medicines Agency, FIMEA.
  • Achieving GMP status permits Nanoform to manufacture an investigational drug, developed using its proprietary CESS nanoparticle engineering platform, for use in clinical trials.
  • The GMP certification represents a very important milestone for Nanoform as it continues to increase the commercial reach of its CESStechnology, which reduces the size of API particles to less than 200nm (and in some cases as small as 10nm) to improve dissolution rates and bioavailability.
  • Prof. Edward Hggstrm, Nanoform CEO, commented: "Achieving GMP status constitutes another landmark moment in Nanoform's history.

Nanoform Awarded GMP Certification

Retrieved on: 
Monday, May 4, 2020

HELSINKI, May 4, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has been awarded a Good Manufacturing Practices (GMP) certification by the Finnish Medicines Agency, FIMEA.

Key Points: 
  • HELSINKI, May 4, 2020 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, has been awarded a Good Manufacturing Practices (GMP) certification by the Finnish Medicines Agency, FIMEA.
  • Achieving GMP status permits Nanoform to manufacture an investigational drug, developed using its proprietary CESS nanoparticle engineering platform, for use in clinical trials.
  • The GMP certification represents a very important milestone for Nanoform as it continues to increase the commercial reach of its CESStechnology, which reduces the size of API particles to less than 200nm (and in some cases as small as 10nm) to improve dissolution rates and bioavailability.
  • Prof. Edward Hggstrm, Nanoform CEO, commented: "Achieving GMP status constitutes another landmark moment in Nanoform's history.

Covid-19 Stimulus Grants for GMP Regulated Companies Offered by InstantGMP and The GMP Collective

Retrieved on: 
Tuesday, March 31, 2020

InstantGMP, Inc. and The GMP Collective want to help by offering Covid-19 Stimulus Grants which we will be awarding to GMP regulated manufacturers.

Key Points: 
  • InstantGMP, Inc. and The GMP Collective want to help by offering Covid-19 Stimulus Grants which we will be awarding to GMP regulated manufacturers.
  • "We are grateful to align with InstantGMP and support the industry with resources and expertise that will provide lasting value" said David Vaillencourt, President of The GMP Collective.
  • InstantGMP, Inc. and The GMP Collective share a common purpose to help FDA regulated companies meet the requirements of current Good Manufacturing Practices.
  • As a manufacturing software company, InstantGMP pioneered accessible, easy-to-use electronic batch record software for products manufactured using GMP.

Delphi Genetics More Than Triples Its Production Capacity and Receives GMP Certification

Retrieved on: 
Monday, March 30, 2020

CHARLEROI, Belgium, March 30, 2020 /PRNewswire/ --Delphi Genetics announces today that it has received the coveted GMP certificate, issued by the AFMPS, covering its brand new state-of-the-art GMP manufacturing suites.

Key Points: 
  • CHARLEROI, Belgium, March 30, 2020 /PRNewswire/ --Delphi Genetics announces today that it has received the coveted GMP certificate, issued by the AFMPS, covering its brand new state-of-the-art GMP manufacturing suites.
  • "The approval of these additional three suites allows Delphi Genetics to very significantly enhance its production capacities for plasmid DNA manufacturing and further assist the development of gene therapy candidates and DNA-based therapies,"commented Franois Blondel, Chairman of the board of Directors and CEO.
  • "This approval, and the capacity expansion, are a very significant step forward in the growth of Delphi Genetics.
  • Various alternatives to treat the current Covid-19 Pandemic involve nucleotide-based approaches that will require the source of GMP Plasmid DNA.

Delphi Genetics More Than Triples Its Production Capacity and Receives GMP Certification

Retrieved on: 
Monday, March 30, 2020

CHARLEROI, Belgium, March 30, 2020 /PRNewswire/ --Delphi Genetics announces today that it has received the coveted GMP certificate, issued by the AFMPS, covering its brand new state-of-the-art GMP manufacturing suites.

Key Points: 
  • CHARLEROI, Belgium, March 30, 2020 /PRNewswire/ --Delphi Genetics announces today that it has received the coveted GMP certificate, issued by the AFMPS, covering its brand new state-of-the-art GMP manufacturing suites.
  • "The approval of these additional three suites allows Delphi Genetics to very significantly enhance its production capacities for plasmid DNA manufacturing and further assist the development of gene therapy candidates and DNA-based therapies,"commented Franois Blondel, Chairman of the board of Directors and CEO.
  • "This approval, and the capacity expansion, are a very significant step forward in the growth of Delphi Genetics.
  • Various alternatives to treat the current Covid-19 Pandemic involve nucleotide-based approaches that will require the source of GMP Plasmid DNA.